Abstract:<span class="paragraphSection">BackgroundAlthough treatment modalities for non-small cell lung cancer (NSCLC) are rapidly evolving, there is insufficient evidence that novel drugs reach elderly patients (aged ≥ 70 years) and improve their outcomes. The purpose of this study was to evaluate the access to treatment in the elderly population with stage IV NSCLC in a real life setting and its impact on survival (OS) over the past 10 years.MethodsWe compared elderly and younger patients with stage IV NSCLC treated at our tertiary cancer centre and its affiliated smaller hospitals. We collected patients and tumor characteristics such as age at diagnosis, gender, smoking history, histology, molecular subtyping, PDL1 expression status and data on treatment types as well as lines. We grouped the enrolled patients into four same size cohorts based on time and age at diagnosis: patients diagnosed 2005-2007 (elderly cohort-I) and 2015-2016 (elderly cohort-II) were compared to cohorts of patients <70 years old diagnosed during the same time periods (young cohorts-I and -II). The characteristics were analysed using Chi-square Test and survival related endpoints with Kaplan-Meier model. A log-rank test was used to test the equality of the survivor functions and a z-Test to assess the differences in survival proportions.Results499 NSCLC cases were retrospectively analysed. Median OS significantly improved in both, the elderly and the young cohorts, over time. OS in the elderly cohort-I and -II was slightly lower (3.7 months and 5.3 months) compared to the young cohorts-I and -II (7.8 and 12.1 months). In the young group 12-months OS was significantly improved over the last 10 years (34% [95%CI 27%-42%] and 52% [95%CI 43%-61%], p = 0.049). There was no significant improvement in the elderly cohorts (18% [95%CI 11%-25% vs. 31% [95%CI 22%-39%], p = 0.29). Therapy with any line of systemic treatment modalities remained lower in the elderly cohorts as compared to younger patients (53% versus 78%).ConclusionsWe observed a significant improvement in OS over the past 10 years in young patients, whereas a similar benefit was not found for the elderly. Our findings highlight a strong need in studying this growing population separately in elderly specific clinical trials.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureS. Schmidt: Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: MSD; Research grant / Funding (institution): BMS; Research grant / Funding (institution): AstraZeneca; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: TAKEDA; Travel / Accommodation / Expenses: Boehringer Ingelheim. M. Fruh: Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. All other authors have declared no conflicts of interest.</span>

Retrospective analysis of effect of different strategies in the treatment of elderly lung adenocarcinoma patients

Long-Term Treatment Outcomes of the Elder Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy or Radiotherapy.

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Efficacy of Platinum Drugs in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer and Their Effects on Prognosis and Survival.

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China

The featore and the prognosis analyising of the elderly advanced lung cancer

[A Retrospective Analysis: Comparison of the Clinical Characteristics and Prognosis in Elderly and Young Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.].

Analysis of Survival Data in Patients with Advanced Non-Small-Cell Lung Cancer Aged 60 Years and Over

Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma.

The evaluations of different age advanced non-small-cell lung cancer patients treated with docetaxel plus platinum combination chemotherapy

Efficacy and Predictors of Egfr Tyrosine Kinase Inhibitors in Chinese Advanced Lung Adenocarcinoma: Analyses of 253 Cases from A Single Institute

Effect of preoperative infusion chemotherapy combined with hyperthermia on sPD-L1 and CEA levels and overall survival of elderly patients undergoing radical resection of lung cancer

Investigation on Advanced Non-Small-Cell Lung Cancer among Elderly Patients Treated with Chinese Herbal Medicine versus Chemotherapy: A Pooled Analysis of Individual Data

Does progress achieved in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) reach the elderly population?

Treatment Results of Elderly Patients with Early Stage of Non-small Cell Lung Cancer which Received Different Target Area Radiotherapy

EGFR-Tyrosine Kinase Inhibitor Combined with Radiotherapy in 105 Patients of Lung Adenocarcinoma with Brain Metastasis: A Retrospective Study of Prognostic Factor Analysis

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

Analysis of Prognostic Factors of Sequential Treatment in 355 Patients with Advanced Non-Small Cell Lung Cancer

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

Survival and Outcomes of Surgical Treatment of the Elderly NSCLC in China: a Retrospective Matched Cohort Study.

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.